Japan · Delayed Price · Currency is JPY Perseus Proteomics Company Description
Perseus Proteomics Inc., a drug discovery biotech venture company, develops antibody drugs against cancer and other diseases in Japan.
The company is involved in the antibody discovery activities; and antibody research support activities comprising hybridoma antibody sequencing, antibody protein production, and contract antibody research activities, as well as supply of antibody products.
Its product pipeline includes PPMX-T001, an anti-hepatocarcinoma antibody; PPMX-T002, an anticancer drug; PPMX-T003, a drug for the treatment of adult T-cell; and PPMX-T004, an antibody drug conjugate.
Perseus Proteomics Inc. has a joint research agreement with ASKA Pharmaceutical Co., Ltd. for the development of new antibody drugs and therapeutic drugs for specific disease areas.
Perseus Proteomics Inc. was incorporated in 2001 and is headquartered in Tokyo, Japan.
| Country | Japan |
| Founded | 2001 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 32 |
| CEO | Takuya Yokokawa |
Contact Details
Address: 30-1 Nihonbashi Hakozakicho Tokyo, 103-0015 Japan | |
| Phone | 81 3 6264 8268 |
| Website | ppmx.com |
Stock Details
| Ticker Symbol | 4882 |
| Exchange | Tokyo Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | April - March |
| Reporting Currency | JPY |
| ISIN Number | JP3836800007 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Takuya Yokokawa | Chief Executive Officer |